Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Zydus Cadila New Oral GLP-1 Agonist ZYOG1 Receives Phase I Permission
Zydus Cadila said that the first molecule of the new class of anti-diabetic drugs called Glucagon Like Peptide-1 (GLP -1) agonists was approved by FDA in May 2005.
Zydus Cadila said that the first molecule of the new class of anti-diabetic drugs called Glucagon Like Peptide-1 (GLP -1) agonists was approved by FDA in May 2005.
GW Pharma claimed that Sativex is the first prescription cannabis medicine and the UK is the first country to grant a full regulatory authorisation for the product. GW
OncoGenex Pharma said that this trial is the first of three Phase 3 trials to be initiated under a global collaboration and license agreement between OncoGenex and Teva
Dyax will retain its rights to subcutaneous DX-88 in other territories, including the US, where DX-88 has been approved by the FDA and is marketed as Kalbitor (ecallantide)
As per the terms of the LOI, the GHLV is expected to pay Pacific an upfront fee, milestone payments for key clinical and regulatory achievements, and royalties on
The first project, the parallel chromatography process, was implemented earlier this year and allows production to run across multiple shifts, effectively doubling the capacity of the current manufacturing
Simulations Plus said that the preliminary revenues for the pharmaceutical software and services portion of the business were up 17.1% to $2.3m. However, Simulations Plus has also reported
Comsol’s new module is built on the Comsol platform to create a single environment where engineers and scientists obtain accurate studies of material transport and chemical reactions of
Activus’ core technologies in drug formulation using proprietary nano-particle processing is expected to form the basis of Sosei’s new platform technology. Activus Pharma said that its Activus Pure
The effectiveness of Tasigna is based on major molecular response and cytogenetic response rates. The study is ongoing and further data will be required to determine long-term outcome.